Blogger's Note: the pdf version is easier to view
Fulltext
PDF(314K) Free
"The ratios of CA-125/CP2 and CA-125/CA19-9 were significantly different after either chemotherapy or recurrence."
"With respect to the pathological type, there were 20 cases of serous carcinoma, 6 cases of mucinous carcinoma, 3 cases of
endometrial carcinoma, 2 cases of clear cell carcinoma
and 4 cases of mixed epithelial carcinoma in the 35 cases
of de novo patients.
For the recurrent patient group there were 25 cases of serous carcinoma, 4 cases of mucinous carcinoma, 2 cases of endometrial carcinoma, 2 cases of clear cell carcinoma, 1 case of mixed epithelial carcinoma, 2 cases of transitional cell carcinoma and 1 case of undifferentiated carcinoma in the 37 cases of recurrent patients."
"With respect to the pathological type, there were 20 cases of serous carcinoma, 6 cases of mucinous carcinoma, 3 cases of
endometrial carcinoma, 2 cases of clear cell carcinoma
and 4 cases of mixed epithelial carcinoma in the 35 cases
of de novo patients.
For the recurrent patient group there were 25 cases of serous carcinoma, 4 cases of mucinous carcinoma, 2 cases of endometrial carcinoma, 2 cases of clear cell carcinoma, 1 case of mixed epithelial carcinoma, 2 cases of transitional cell carcinoma and 1 case of undifferentiated carcinoma in the 37 cases of recurrent patients."
Conclusions Serum tumor marker expression in patients with EOC or PSPC may change after chemotherapy or recurrence, indicating that in addition to the markers that are abnormal before surgery, those markers that are normal
should also be monitored during chemotherapy and follow-up.
